13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
Geneva, Switzerland
March 26 – 29, 2014

FOCUS: new targets and drugs for the treatment of Alzheimer’s disease and novel approaches to current therapy.

For more information, visit www.ad-springfield.com
Organizers: Ezio Giacobini and Gabriel Gold

Visit www.ad-springfield.com by scanning this QR code with your smartphone.
Speakers’ abstracts from the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy have been published as a supplement to Neurobiology of Aging. A copy of the supplement will be handed to all participants in the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy.

This Program Book contains the Index to Poster Abstracts from the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. The text of the Poster Abstracts can be found by visiting www.ad-springfield.com
Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Southern Illinois University School of Medicine, the University of Geneva, Geneva University Hospitals, and the Karolinska Institutet. The Southern Illinois University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit

Southern Illinois University School of Medicine designates this live activity for a maximum of 20 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Industry-sponsored sessions are not designated for AMA PRA Category 1 credit.
## Table of Contents

Supporters ................................................................. 4
International Springfield Symposia .......................... 5
Organizers and Coordinators ................................. 6
International Scientific Advisory Committee ............. 6
Invited speakers ........................................................ 7

*The 2012 Speakers’ Abstracts have been published as a supplement in* Neurobiology of Aging, May, 2012, Vol 33 No. S1

Schedule at a Glance ................................................. 8-10
Program ................................................................. 11-24

Index of Poster Abstracts (*alphabetical by presenting author*) .......... 25-38
Index of Posters by Category ..................................... 39-48
Core Supporters

AstraZeneca
Elan Corporation
Eli Lilly and Company
H. Lundbeck A/S
Novartis Pharma AG
Pfizer, Inc.

Supporters

AC Immune, Switzerland
Affiris GmbH, Austria
Baxter BioScience, Baxter Healthcare Corp. USA
GE Healthcare
Neurophage, USA
Probiodrug, Germany
Worldwide Clinical Trials, USA

Special thanks go to the City of Stockholm and the Stockholm County Council for their generous support in hosting the welcome reception at the City Hall. The reception is free of charge for participants.
International Springfield Symposia

March 18-19, 1988, Springfield
International Springfield Symposium on Advances in Alzheimer Therapy

May 3-5, 1991, Springfield
2nd International Springfield Symposium on Advances in Alzheimer Therapy

May 11-16, 1994, Springfield
3rd International Springfield Symposium on Advances in Alzheimer Therapy

April 10-14, 1996, Nice
4th International Nice/Springfield Symposium on Advances in Alzheimer Therapy

April 15-18, 1998, Geneva
5th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy

April 5-8, 2000, Stockholm
6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy

April 3-6, 2002, Geneva
7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy

April 14-17, 2004, Montreal
8th International Montreal/Springfield Symposium on Advances in Alzheimer Therapy

April 19-22, 2006, Geneva
9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy

February 28, 29 - March 1, 2008, Hong Kong
10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy

March 24-27, 2010, Geneva
11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy

May 9-12, 2012, Stockholm
12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy

March 26-29, 2014 Geneva
13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
Organizers
Ezio Giacobini, MD, PhD, Geneva
Gabriel Gold, MD, Geneva
Agneta Nordberg, MD, PhD, Stockholm

Coordinators
Ann Hamilton (USA)
Christine Mesmer (Europe)

International Scientific Advisory Committee
Karen Ashe, USA
Robert Becker, USA
Kaj Blennow, Sweden
Constantin Bouras, Switzerland
Claudio A. Cuello, Canada
Bruno Dubois, France
Rodger J. Elble, USA
Abraham Fisher, Israel
Serge Gauthier, Canada
Panteleimon Giannakopoulos, Switzerland
Harald Hampel, Germany
Christoph Hock, Switzerland
Khalid Iqbal, USA
Amos Korczyn, Israel
Eva-Maria Mandelkow, Germany
John C. Morris, USA
Roger Nitsch, Switzerland
Jean-Marc Orgogozo, France
Giancarlo Pepeu, Italy
Philippe Robert, France
Dale Schenk, USA
Lon S. Schneider, USA
Dennis J. Selkoe, USA
Hilkka Soininen, Finland
Rudolph Tanzi, USA
Bruno Vellas, France
Bengt Winblad, Sweden
Manfred Windisch, Austria
# Invited Speakers

1. Susan Abushakra  
2. Niels Andreasen  
3. Karen Ashe  
4. Alireza Atri  
5. Clive Ballard  
6. Robert Becker  
7. Howard Bergman  
8. Kaj Blennow  
9. Constantin Bouras  
10. Amalia Bruni  
11. Luc Buée  
12. Zsolt Cselényi  
13. Claudio A. Cuello  
14. Jeffrey Cummings  
15. Taher Darreh-Shori  
16. Hans-Ulrich Demuth  
17. Rachelle Doody  
18. Murali Doraiswamy  
20. Rodger J. Elble  
21. Maria Eriksdotter Jönhagen  
22. Timo Erkinjuntti  
23. Martin Farlow  
25. Richard Fisher  
26. Nick Fox  
27. Paul Francis  
28. Laura Fratiglioni  
29. Giovanni Frisoni  
30. Lutz Fröhlich  
31. Serge Gauthier  
32. David Gelmont  
33. Ezio Giacobini  
34. Panteleimon Giannakopoulos  
35. Gabriel Gold  
36. Illana Gozes  
37. Harald Hampel  
38. François Herrmann  
39. Christoph Hock  
40. David M. Holtzman  
41. Khalid Iqbal  
42. Jianping Jia  
43. Roy Jones  
44. Andrew Kertesz  
45. Gene Kinney  
46. Miia Kivipelto  
47. William Klein  
48. William Klunk  
49. Amos Korczyn  
50. Gary Landreth  
51. Constantine Lyketsos  
52. Pierre Magistretti  
53. Eva-Maria Mandelkow  
54. Markus Mandler  
55. Amelia Marutle  
56. Colin Masters  
57. Ian McKeith  
58. Daniel Michaelson  
59. José Luis Molinuevo  
60. John C. Morris  
61. Lennart Mucke  
62. Elliott Mufson  
63. Andreas Muhs  
64. Roger Nitsch  
65. Agneta Nordberg  
66. Jean-Marc Orgogozo  
67. Giulio Maria Pasinetti  
68. Michela Pievani  
69. Juha Rinne  
70. Henry Riordan  
71. Philippe Robert  
72. Christopher Rowe  
73. Cristina Sampao  
74. Philip Scheltens  
75. Dale Schenk  
76. Achim Schneeberger  
77. Lon S. Schneider  
78. Ingmar Skoog  
79. Daniel Skovronsky  
80. Gary Small  
81. A. David Smith  
82. Hilkka Soininen  
83. Beka Solomon  
84. Hermona Soreq  
85. Maria Grazia Spillantini  
86. Rudolph Tanzi  
87. Pierre Tariot  
88. Marco Trabucchi  
89. Victor L. Villemagne  
90. Dominic Walsh  
91. Marta Weinstock-Rosin  
92. David Wilkinson  
93. Anders Wimo  
94. Bengt Winblad  
95. Manfred Windisch  
96. Moussa Youdim  
97. Orazio Zanetti  
98. Dina Zekry
## May 9, 2012

### Schedule at a Glance

#### Wednesday, May 9, 2012

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 18:00</td>
<td>Registration at the City Conference Centre (<em>Folkets Hus</em>), Stockholm</td>
</tr>
<tr>
<td>16:45 – 17:15</td>
<td>Welcome address</td>
</tr>
<tr>
<td>17:15 – 18:00</td>
<td>Opening lecture</td>
</tr>
<tr>
<td>19:00 – 21:00</td>
<td>Welcome reception</td>
</tr>
</tbody>
</table>

#### Thursday, May 10, 2012

**Room A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 – 08:35</td>
<td>State of the art lecture: Validation and implementation of the new diagnostic criteria for Alzheimer's disease</td>
</tr>
<tr>
<td>08:35 – 09:55</td>
<td>Are we Ready to Perform Clinical Trials in Early Alzheimer's Disease Patients?</td>
</tr>
<tr>
<td>09:55 – 10:45</td>
<td>Break</td>
</tr>
<tr>
<td>12:20 – 13:45</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:45 – 15:25</td>
<td>Combination Treatment in Alzheimer's Disease <em>Lundbeck mini-symposium</em></td>
</tr>
<tr>
<td>15:25 – 15:55</td>
<td>Break</td>
</tr>
<tr>
<td>15:55 – 17:35</td>
<td>Evolving Criteria for Alzheimer's Disease: Sharing Perspectives on the Path Forward <em>Pfizer, Inc. mini-symposium</em></td>
</tr>
</tbody>
</table>

**Room B**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 – 08:35</td>
<td>State of the art lecture: Concomitant activation of G-protein coupled receptors (GPCR) and sigma l receptor (Sig1R): A novel pharmacological concept in the treatment of Alzheimer's disease</td>
</tr>
<tr>
<td>08:35 – 09:55</td>
<td>The Cholinergic System and Alzheimer's Disease – Year 2012</td>
</tr>
<tr>
<td>09:55 – 10:45</td>
<td>Break</td>
</tr>
<tr>
<td>10:45 – 12:20</td>
<td>Plenary session in room A and B: see program in room A</td>
</tr>
<tr>
<td>12:20 – 13:45</td>
<td>Lunch</td>
</tr>
<tr>
<td>13:45 – 14:05</td>
<td>State of the art lecture: Testing new treatments with CSF biomarkers in early Alzheimer's disease patients</td>
</tr>
<tr>
<td>15:25 – 15:55</td>
<td>Break</td>
</tr>
<tr>
<td>16:15 – 17:35</td>
<td>Phosphorylated-Tau: The Hottest Target in Town?</td>
</tr>
</tbody>
</table>
# May 9, 2012
## Schedule at a Glance

### Friday, May 11, 2012

<table>
<thead>
<tr>
<th>Room A</th>
<th>Room B</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08:30 – 08:50</strong></td>
<td>State of the art lecture:</td>
</tr>
<tr>
<td><strong>Life course epidemiology in dementia – state of the art</strong></td>
<td>The brain of very old people:</td>
</tr>
<tr>
<td><strong>08:50 – 10:10</strong></td>
<td>How does it work?</td>
</tr>
<tr>
<td>Immunization: Is it the Right Solution?</td>
<td>New Diagnostic Tools</td>
</tr>
<tr>
<td><strong>10:10 – 10:40</strong></td>
<td>Break</td>
</tr>
<tr>
<td><strong>10:40 – 12:20</strong></td>
<td>Advances in Molecular Imaging in Alzheimer's disease</td>
</tr>
<tr>
<td><em>AstraZeneca mini-symposium</em></td>
<td></td>
</tr>
<tr>
<td><strong>12:20 – 13:45</strong></td>
<td>Lunch</td>
</tr>
<tr>
<td><strong>13:45 – 14:05</strong></td>
<td>State of the art lecture:</td>
</tr>
<tr>
<td><em>Astrocyte-neuron metabolic coupling in Alzheimer's disease</em></td>
<td>Why have we failed to cure Alzheimer's disease?</td>
</tr>
<tr>
<td></td>
<td><em>Partially supported by AC Immune</em></td>
</tr>
<tr>
<td><strong>14:05 – 15:25</strong></td>
<td>Emerging Novel Therapeutic Targets I</td>
</tr>
<tr>
<td>Using Imaging Markers to Study Drug Effects in Alzheimer's disease</td>
<td>Vascular Dementia</td>
</tr>
<tr>
<td><em>Partially supported by GE Healthcare</em></td>
<td></td>
</tr>
<tr>
<td><strong>15:25 – 15:55</strong></td>
<td>Break</td>
</tr>
<tr>
<td><strong>15:55 – 17:35</strong></td>
<td>State of the art lecture:</td>
</tr>
<tr>
<td>High-dose Cholinesterase Inhibition: A New Approach to Alzheimer Therapy?</td>
<td>Anti-oxidants in Alzheimer's disease and MCI</td>
</tr>
<tr>
<td><em>Novartis mini-symposium</em></td>
<td></td>
</tr>
<tr>
<td><strong>16:15 - 17:35</strong></td>
<td>Caring for Patients with Dementia</td>
</tr>
</tbody>
</table>
## May 9 12, 2012
### Schedule at a Glance

#### Saturday, May 12, 2012

**Room A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 10:10</td>
<td>The Emerging Clinical Profile of Oral Scylo-inositol (ELND005) in Alzheimer’s Disease: A Dual Mechanism of Action?</td>
<td><em>Elan mini-symposium</em></td>
</tr>
<tr>
<td>10:10 – 10:40</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:40 – 11:00</td>
<td>State of the art lecture: CSF sample acquisition and analyses for translational research purposes</td>
<td><em>Supported by Worldwide Clinical Trials, USA</em></td>
</tr>
<tr>
<td>11:00 – 12:20</td>
<td>Non-Alzheimer’s Disease Dementia: Diagnosis &amp; Treatment</td>
<td></td>
</tr>
<tr>
<td>12:20 – 13:45</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13:45 – 14:05</td>
<td>State of the art lecture: Cognitive reserve and survival</td>
<td></td>
</tr>
<tr>
<td>14:05 – 15:30</td>
<td>Round Table: Let’s Treat Familial Alzheimer’s Disease (EOFAD)</td>
<td></td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Closing remarks in room A</td>
<td></td>
</tr>
<tr>
<td>18:30 – 22:00</td>
<td><strong>Speakers dinner</strong> <em>(by invitation)</em></td>
<td></td>
</tr>
</tbody>
</table>

**Room B**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 08:50</td>
<td>State of the art lecture: Micro RNAs: a new therapeutic target in Alzheimer’s disease</td>
<td></td>
</tr>
<tr>
<td>08:50 – 10:10</td>
<td>Emerging Novel Therapeutic Targets II</td>
<td><em>Partially supported by Probiodrug AG</em></td>
</tr>
<tr>
<td>10:10 – 10:40</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:40 – 12:20</td>
<td>Emerging Novel Therapeutic Targets III</td>
<td><em>Partially supported by Affris GmbH NeuroPhage Pharmaceuticals, and Baxter Healthcare Corp.</em></td>
</tr>
<tr>
<td>12:20 – 13:45</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>14:05 – 15:25</td>
<td>Is ApoE a Valid Target for Treatment of Alzheimer’s Disease?</td>
<td></td>
</tr>
<tr>
<td>15:30 – 16:00</td>
<td>Closing remarks in room A</td>
<td></td>
</tr>
<tr>
<td>18:30 – 22:00</td>
<td><strong>Speakers dinner</strong> <em>(by invitation)</em></td>
<td></td>
</tr>
</tbody>
</table>
Program
12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy
May 9 – 12, 2012

Wednesday, May 9, 2012

14:00 – 18:00  Registration

16:45 – 17:15  Welcome address
Ezio Giacobini, Gabriel Gold and Agneta Nordberg, Organizers
Arnaud Perrier, Head of the Department of Internal Medicine, Rehabilitation and Geriatrics, Geneva University Hospitals (Geneva, Switzerland)
Kevin Dorsey, Dean, Southern Illinois University School of Medicine (Springfield, USA)
Harriet Wallberg Henriksson, Dean, Karolinska Institutet (Stockholm, Sweden)

17:15 – 18:00  Opening Lecture
Bengt Winblad (Stockholm, Sweden)
Alzheimer Therapy: Present and Future

19:00 – 21:00  Welcome Reception at the City Hall
(offered by the City of Stockholm and the Stockholm County Council)

It is the policy of Southern Illinois University School of Medicine to ensure balance, independence, objectivity and scientific rigor in its educational programs. All faculty participating are expected to disclose to the program audiences any real or apparent conflicts of interest related to the content of their presentation.

This program reflects changes through March 30, 2012.
Thursday, May 10, 2012
Room A

08:15 – 08:35  State of the art lecture: Bruno Dubois (Paris, France)
Validation and implementation of the new diagnostic criteria for Alzheimer’s disease

■ Are we Ready to Perform Clinical Trials in Early Alzheimer’s Disease Patients?
Chairs: Serge Gauthier and Lon Schneider

08:35 – 08:55  Serge Gauthier (Montreal, Canada)
The challenge of treating prodromal Alzheimer’s disease patients

08:55 – 09:15  Lon Schneider (Los Angeles, USA)
Are we ready to perform clinical trials in early Alzheimer’s disease patients?
Which patients, which outcomes?

09:15 – 09:35  Cristina Sampaio (Lisbon, Portugal)
A regulatory viewpoint

09:35 – 09:55  Robert Becker (South Freeport, USA)
Are we ready with a new trial design?

09:55 – 10:45  Break

Special plenary session in rooms A and B

■ Alzheimer’s Disease: The Health Challenge of the 21st Century
Chairs: Agneta Nordberg and Ezio Giacobini

10:45 – 11:00  Agneta Nordberg (Stockholm, Sweden)
Introduction

11:00 – 11:20  John Morris (St. Louis, USA)
Alzheimer’s disease: What have we learned and where must we go?

11:20 – 11:40  Rudolph Tanzi (Charlestown, USA)
What are genetic studies teaching us about how to treat Alzheimer’s disease?

11:40 – 12:00  Miia Kivipelto (Stockholm, Sweden)
Prevention of Alzheimer’s disease, is it possible?

12:00 – 12:20  Marco Trabucchi (Brescia, Italy)
Caring for patients with dementia

12:20 – 13:45  Lunch
Thursday, May 10, 2012
Room A

### Combination Treatment in Alzheimer’s Disease
**Chair: David Wilkinson**

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:45 – 13:50</td>
<td>Chairman's introduction: David Wilkinson (Southampton, UK)</td>
<td></td>
</tr>
<tr>
<td>13:50 – 14:15</td>
<td>Murali Doraiswamy (Durham, USA)</td>
<td>Alzheimer's disease - developments and trends</td>
</tr>
<tr>
<td>14:15 – 14:40</td>
<td>Paul Francis (London, UK)</td>
<td>What could be the pre-clinical rationale for combination treatment in Alzheimer's disease?</td>
</tr>
<tr>
<td>14:40 – 15:10</td>
<td>Alireza Atri (Boston, USA)</td>
<td>Combination treatment in Alzheimer’s disease - clinical aspects</td>
</tr>
<tr>
<td>15:10 – 15:25</td>
<td>Panel discussion</td>
<td></td>
</tr>
</tbody>
</table>

15:25 – 15:55 Break

### Evolving Criteria for Alzheimer’s Disease: Sharing Perspectives on the Path Forward
**A Panel Discussion Chaired by Jeffrey Cummings (Las Vegas, USA)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:55 – 17:35</td>
<td>In this symposium, Dr. Jeffrey Cummings will chair a discussion where expert panelists will provide their perspectives on the evolving diagnostic criteria. The commentary and discussions will focus on the implications of key commonalities and differences between the criteria and highlight approaches to moving the criteria forward in an effort to develop a more cohesive diagnostic framework for the practicing physician. The session will include ample time for discussion and questions from the audience.</td>
</tr>
</tbody>
</table>
Thursday, May 10, 2012
Room B

08:15 – 08:35  State of the art lecture: Abraham Fisher (Ness Ziona, Israel)
Concomitant activation of G-protein coupled receptors (GPCR) and sigma 1 receptor (Sig1R): A novel pharmacological concept in the treatment of Alzheimer’s disease (AD)

The Cholinergic System and Alzheimer’s Disease - Year 2012
Chairs: Giancarlo Pepeu and Israel Hanin
(Session dedicated to David Bowen)

08:35 – 08:55  Elliott Mufson (Chicago, USA)
Cholinergic and amyloid activity in prodromal Alzheimer’s disease:
Implications for disease treatment

08:55 – 09:15  Claudio Cuello (Montreal, Canada)
NGF and Alzheimer’s disease

09:15 – 09:35  Taher Darreh-Shori (Stockholm, Sweden)
The relationship between cholinesterases and Alzheimer’s pathology

09:35 – 09:55  Amelia Marutle (Stockholm, Sweden)
Revamping the cholinergic system in Alzheimer’s disease: Experience from stem cell studies

09:55 - 10:45  Break

Special plenary session in rooms A and B

10:45 – 12:20  Alzheimer’s Disease: The Health Challenge of the 21st Century (see room A)

12:20 – 13:45  Lunch
Thursday, May 10, 2012
Room B

13:45 – 14:05  State of the art lecture: Kaj Blennow (Mölndal, Sweden)
Testing new treatments with CSF biomarkers in early Alzheimer’s disease patients

A-Beta Oligomers and Tau: Partners in Crime?
Chairs: Colin Masters and Lennart Mucke

14:05 – 14:25  Lennart Mucke (San Francisco, USA)
Mechanisms and treatment of A-beta-induced neuronal dysfunction
14:25 – 14:45  Dominic Walsh (Dublin, Ireland)
Getting to grips with water-soluble brain-derived A-beta dimers
14:45 – 15:05  William Klein (Evanston, USA)
Is tau phosphorylation the fuse and toxic A-beta the match?
15:05 – 15:25  Colin Masters (Parkville, Australia)
A-beta oligomers as diagnostic and therapeutic targets for Alzheimer’s disease

15:25 – 15:55  Break

15:55 – 16:15  State of the art lecture: Luc Buée (Lille, France)
Innovative therapeutic strategies for TAU pathology: From cholesterol
metabolism to immunotherapy

Phosphorylated-Tau: The Hottest Target in Town?
Chairs: Eva Mandelkow and Karen Ashe

16:15 – 16:35  Eva Mandelkow (Hamburg, Germany)
Reversibility of cognitive decline and synapse loss in regulatable mice with
tau pathology
16:35 – 16:55  Karen Ashe (Minneapolis, USA)
Evidence in humans linking a specific amyloid-beta oligomer to tau pathobiology
16:55 – 17:15  Khalid Iqbal (Staten Island, USA)
Promise and feasibility of inhibition of tau's abnormal hyperphosphorylation
17:15 – 17:35  Maria Grazia Spillantini (Cambridge, UK)
Tauopathies: a single therapy for all?
12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy

Friday, May 11, 2012
Room A

08:30 – 08:50  State of the art lecture: Laura Fratiglioni (Stockholm, Sweden)
Life course epidemiology in dementia – state of the art

■ Immunization: Is it the Right Solution?
Chairs: Roger Nitsch and Dale Schenk

08:50 – 09:10  Roger Nitsch (Zurich, Switzerland)
Immunotherapy of protein aggregation diseases

09:10 – 09:30  Dale Schenk (South San Francisco, USA)
Preclinical and clinical considerations for A-beta immunotherpay

09:30 – 09:50  Christoph Hock (Zurich, Switzerland)
Antibody therapy of Alzheimer’s disease

09:50 – 10:10  Ezio Giacobini (Geneva, Switzerland)
Taming beta-amyloid: Is that the solution?

10:10 – 10:40  Break

Mini-Symposium supported by AstraZeneca

■ Advances in Molecular Imaging in Alzheimer’s Disease
Chairs: Agneta Nordberg and Lars Farde

10:40 – 11:00  Agneta Nordberg (Stockholm, Sweden)
A decade of amyloid PET imaging: Advances in neuroinflammation

11:00 – 11:20  Daniel Skovronsky (Philadelphia, USA)
Amyvid (Florbetapir) development

11:20 – 11:40  Zsolt Cselényi (Södertälje, Sweden)
Early clinical development of amyloid-beta specific PET radioligand (18F) AZD4694

11:40 – 12:00  Victor Villemagne (Heidelberg, Australia)
In vivo tau imaging with PET

12:00 – 12:20  Round table discussion

12:20 – 13:45  Lunch
Friday, May 11, 2012
Room A

13:45 – 14:05  State of the art lecture: Pierre Magistretti (Lausanne, Switzerland)
Astrocyte-neuron metabolic coupling in Alzheimer’s disease

Session partially supported by GE Healthcare

- Using Imaging Markers to Study Drug Effects in Alzheimer’s Disease
  Chairs: Bill Klunk and Nick Fox

  14:05 – 14:25  Bill Klunk (Pittsburgh, USA)
The contribution of PET amyloid imaging to the study of drug effects
  14:25 – 14:45  Nick Fox (London, UK)
MRI in the evaluation of therapeutic effects in clinical trials in early and
presymptomatic Alzheimer’s disease
  14:45 – 15:05  Giovanni Frisoni (Brescia, Italy)
MRI, hippocampal atrophy and cognition
  15:05 – 15:25  Juha Rinne (Turku, Finland)
Following drug effects with PET imaging markers

15:25 – 15:55  Break

Mini-Symposium supported by Novartis

- High-dose Cholinesterase Inhibition: A New Approach to Alzheimer’s Therapy?
  Chairs: Gary Small and Ezio Giacobini

  15:55 – 16:00  Chairman’s introduction: Gary Small (USA) and Ezio Giacobini (Switzerland)
  16:00 – 16:20  Gary Small (Los Angeles, USA)
Pharmacological rationale for cholinesterase inhibition in Alzheimer’s disease
  16:20 – 16:40  Martin Farlow (Indianapolis, USA)
Importance of achieving optimal cholinesterase inhibitor dose
  16:40 – 17:00  Niels Andreasen (Stockholm, Sweden)
The underlying mechanism of action of cholinesterase inhibitors and its
implications for long term Alzheimer’s disease management
  17:00 – 17:20  Lutz Fröhlich (Mannheim, Germany)
High-dose rivastigmine patch: results from the OPTIMA study
  17:20 – 17:35  Round table discussion / Q&A session
Friday, May 11, 2012
Room B

08:30 – 08:50  
State of the art lecture: Constantin Bouras (Geneva, Switzerland)
The brain of very old people: How does it work?

- New Diagnostic Tools
  Chairs: Hilkka Soininen and Panteleimon Giannakopoulos

  08:50 – 09:10  
  Hilkka Soininen (Kuopio, Finland)
  Predict Alzheimer’s disease tools for early diagnosis

  09:10 – 09:30  
  Harald Hampel (Frankfurt, Germany)
  Novel hypothesis-based Alzheimer’s disease prediction biomarkers in blood and CSF

  09:30 – 09:50  
  Jean-Marc Orgogozo (Bordeaux, France)
  Prediction of dementia with simple clinical criteria in elderly subjects

  09:50 – 10:10  
  Panteleimon Giannakopoulos (Geneva, Switzerland)
  EEG-based prediction of rapid cognitive decline in MCI

10:10 – 10:40  
Break

10:40 – 11:00  
State of the art lecture: Amos Korczyn (Ramat Aviv, Israel)
Why have we failed to cure Alzheimer’s disease?

Session partially supported by AC Immune, Switzerland

- Emerging Novel Therapeutic Targets I
  Chairs: Marta Weinstock and Andreas Muhs

  11:00 – 11:20  
  Marta Weinstock (Jerusalem, Israel)
  Ladostigil, a novel multifunctional drug for the prevention and treatment of Alzheimer’s disease

  11:20 – 11:40  
  Andreas Muhs (Lausanne, Switzerland)
  Novel phosho-Tau specific liposome-based vaccines to treat Tau pathology

  11:40 – 12:00  
  Moussa Youdim (Haifa, Israel)
  Novel new multi target anti Alzheimer drugs with neuroprotective and neurorestorative activities

  12:00 – 12:20  
  A. David Smith (Oxford, UK)
  Disease-modification in mild cognitive impairment by lowering homocysteine

12:20 – 13:45  
Lunch
Friday, May 11, 2012
Room B

13:45 – 14:05  
*State of the art lecture: Christopher Rowe* (Melbourne, Australia)
Brain imaging in early detection of Alzheimer’s disease and other dementias

### Vascular Dementia
**Chairs: Gabriel Gold and Timo Erkinjuntti**

14:05 – 14:25  
**Gabriel Gold** (Geneva, Switzerland)
Cerebral microinfarcts: a key target in vascular cognitive impairment?

14:25 – 14:45  
**Philip Scheltens** (Amsterdam, The Netherlands)
Cerebral microbleeds: identification, prevalence and clinical relevance

14:45 – 15:05  
**Timo Erkinjuntti** (Helsinki, Finland)
Small vessel disease

15:05 – 15:25  
**Ingmar Skoog** (Göteborg, Sweden)
Influence of mid-life risk factors on late life cognitive and white matter changes: how should we time preventive interventions?

15:25 – 15:55  
**Break**

15:55 – 16:15  
*State of the art lecture: Dina Zekry* (Geneva, Switzerland)
Anti-oxidants in Alzheimer’s disease and MCI

### Caring for Patients with Dementia
**Chairs: Arnaud Perrier and Howard Bergman**

16:15 – 16:35  
**Orazio Zanetti** (Brescia, Italy)
Non-pharmacological intervention and caregiver support

16:35 – 16:55  
**Philippe Robert** (Nice, France)
Management of neuropsychiatric symptoms in dementia

16:55 – 17:15  
**Howard Bergman** (Montreal, Canada)
How should we structure care for Alzheimer patients?

17:15 – 17:35  
**Anders Wimo** (Stockholm, Sweden)
Global pharmacoeconomics of Alzheimer’s disease in light of potential cost effectiveness of disease modifying treatment
# The Emerging Clinical Profile of Oral Scyllo-inositol (ELND005) in Alzheimer’s Disease: A Dual Mechanism of Action?

**Chairs:** Agneta Nordberg and Dale Schenk

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 08:50</td>
<td>Gene Kinney (South San Francisco, USA)</td>
<td>Overview of amyloid and non-amyloid targets in AD drug development: Where does ELND005 fit in</td>
</tr>
<tr>
<td>08:50 – 09:10</td>
<td>Constantine Lyketsos (Baltimore, USA)</td>
<td>Who are the responders to amyloid-based drugs? What we learned from ELND005 data</td>
</tr>
<tr>
<td>09:10 – 09:30</td>
<td>Susan Abushakra (San Francisco, USA)</td>
<td>What constitutes evidence of target engagement in AD trials? ELND005 CNS pharmaco-kinetics, biomarker, and safety profile</td>
</tr>
<tr>
<td>09:30 – 09:50</td>
<td>Pierre Tariot (Phoenix, USA)</td>
<td>Neuropsychiatric symptoms in AD: Novel analytical approaches for disease modification trials</td>
</tr>
<tr>
<td>09:50 – 10:10</td>
<td>Roy Jones (Bath, UK)</td>
<td>Optimizing treatment success with early intervention: Is mild AD dementia early enough?</td>
</tr>
</tbody>
</table>

## Break

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 – 10:40</td>
<td><strong>State of the art lecture:</strong> Henry Riordan (King of Prussia, USA)</td>
</tr>
<tr>
<td>10:40 – 11:00</td>
<td>CSF sample acquisition and analyses for translational research purposes</td>
</tr>
</tbody>
</table>

# Non-Alzheimer’s Disease Dementia: Diagnosis and Treatment

**Chairs:** Rodger Elble and Ian McKeith

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:20</td>
<td>Rodger Elble (Springfield, USA)</td>
<td>How similar and disimilar are AD, PD, DLB and FTD?</td>
</tr>
<tr>
<td>11:20 – 11:40</td>
<td>Clive Ballard (London, UK)</td>
<td>Optimal treatment for Parkinson patients with cognitive disorders</td>
</tr>
<tr>
<td>11:40 – 12:00</td>
<td>Ian McKeith (New Castle, UK)</td>
<td>Early diagnosis for Lewy body disease and treatment</td>
</tr>
<tr>
<td>12:00 – 12:20</td>
<td>Andrew Kertesz (London, Canada)</td>
<td>Fronto-temporal degeneration, an update</td>
</tr>
</tbody>
</table>

## Lunch

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 – 13:45</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
Saturday, May 12, 2012
Room A

13:45 – 14:05  State of the art lecture: **François Herrmann** (Geneva, Switzerland)
Cognitive reserve and survival

Round Table: Let’s Treat Familial Alzheimer’s Disease (EOFAD)
Chairs: Serge Gauthier and Jianping Jia

14:05 – 14:15  **Serge Gauthier** (Montreal, Canada)
EOFAD: Opportunities for proof-of-concept studies to modify
disease progression

14:15 – 14:25  **Amalia Bruni** (Lamezia Terme, Italy)
Let’s treat familial Alzheimer’s disease - Genetic aspects

14:25 – 14:35  **Agneta Nordberg** (Stockholm, Sweden)
EOFAD: Imaging and genetics

14:35 – 14:45  **Jianping Jia** (Beijing, China)
Chinese early-onset familial Alzheimer’s disease

14:45 – 14:55  **John Morris** (St. Louis, USA)
EOFAD: Update on dominantly inherited Alzheimer network (DIAN)

14:55 – 15:30  General discussion

15:30 – 16:00  Closing remarks

18:30 – 22:00  **Speakers dinner** (by invitation)
### Saturday, May 12, 2012
**Room B**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 08:30 – 08:50 | State of the art lecture: **Hermona Soreq** (Jerusalem, Israel)  
Micro RNAs: a new therapeutic target in Alzheimer’s disease |

#### Session partially supported by Probiodrug AG, Germany

**Emerging Novel Therapeutic Targets II**  
Chairs: Hans-Ulrich Demuth and Beka Solomon

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:50 – 09:10</td>
<td><strong>Hans-Ulrich Demuth</strong> (Halle, Germany)</td>
<td>Inhibition of Glutaminyl cyclase targeting neurodegeneration and neuroinflammation in Alzheimer’s disease</td>
</tr>
<tr>
<td>09:10 – 09:30</td>
<td><strong>Illana Gozes</strong> (Ramat Aviv, Israel)</td>
<td>Dovunetide: a neuroprotective approach to treat neurodegenerative diseases</td>
</tr>
<tr>
<td>09:30 – 09:50</td>
<td><strong>Beka Solomon</strong> (Tel Aviv, Israel)</td>
<td>Beneficial effect of anti APP antibodies on Alzheimer’s pathology</td>
</tr>
<tr>
<td>09:50 – 10:10</td>
<td><strong>Maria Eriksdotter Jönhagen</strong> (Stockholm, Sweden)</td>
<td>Cell therapy with nerve growth factor (NGF) in Alzheimer’s disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 – 10:40</td>
<td>Break</td>
</tr>
</tbody>
</table>

#### Session partially supported by Affiris GmbH, Austria; NeuroPhage Pharmaceuticals, USA and Baxter Bioscience, Baxter Healthcare Corp. USA

**Emerging Novel Therapeutic Targets III**  
Chairs: Bengt Winblad and Achim Schneeberger

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:40 – 11:00</td>
<td><strong>Markus Mandler</strong> (Vienna, Austria)</td>
<td>Affitope® – Based vaccines: A novel and safe immunotherapeutic strategy for neurodegenerative diseases</td>
</tr>
<tr>
<td>11:00 – 11:20</td>
<td><strong>Achim Schneeberger</strong> (Vienna, Austria)</td>
<td>Affitope® Alzheimer vaccines – Results from phase I support the further clinical development of Affitope AD02</td>
</tr>
<tr>
<td>11:20 – 11:40</td>
<td><strong>Giulio Pasinetti</strong> (New York, USA)</td>
<td>Repurposing anti-hypertensive drugs for Alzheimer’s disease</td>
</tr>
<tr>
<td>11:40 – 12:00</td>
<td><strong>Richard Fisher</strong> (Cambridge, USA)</td>
<td>NPT002: A novel approach for targeting A-beta amyloid and tau aggregates in Alzheimer’s disease</td>
</tr>
<tr>
<td>12:00 – 12:20</td>
<td><strong>David Gelmont</strong> (Westlake Village, USA)</td>
<td>The safety and effectiveness of immune globulin intravenous (human), for the treatment of mild to moderate Alzheimer’s disease</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:20 – 13:45</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
Saturday, May 12, 2012  
**Room B**

13:45 – 14:05  
*State of the art lecture: Manfred Windisch* (Graz, Austria)  
Animal models for preclinical testing of early Alzheimer’s disease?

**Is ApoE a Valid Target for Treatment of Alzheimer’s Disease?**  
**Chairs: Daniel Michaelson and David Holtzman**

14:05 – 14:25  
Daniel Michaelson (Tel Aviv, Israel)  
ApoE4 potentiates the amyloid cascade and inhibits neuroprotective mechanisms: prevention of these effects by DHA diet

14:25 – 14:45  
Michela Pievani (Brescia, Italy)  
Relation of ApoE to brain structure and function in Alzheimer’s disease and aging

14:45 – 15:05  
David Holtzman (St. Louis, USA)  
Effect of anti-apoE antibodies on A-beta pathology and accumulation

15:05 – 15:25  
Gary Landreth (Cleveland, USA)  
ApoE-directed therapeutics for the treatment of Alzheimer’s disease

15:30 – 16:00  
**Closing remarks in room A**

18:30 – 22:00  
Speakers dinner (by invitation)
Posters

Posters will be mounted on Wednesday, May 9, beginning at 13h00. They will be displayed until Friday, May 11, at 17h00. While there is no formal poster presentation time, delegates are invited to view the posters during coffee and luncheon breaks. Poster presenters are encouraged to be at their posters during these times.

Poster stands will be removed on Friday, May 11, after 17h30. Poster presenters should remove their posters before this time. The symposium organizers cannot be responsible for posters that are not removed by the presenters.
<table>
<thead>
<tr>
<th>Category</th>
<th>Authors &amp; Titles [Note: Presenting author is underlined.]</th>
</tr>
</thead>
</table>
| 1 E      | **Georg Adler**, Y. Ko-Inoshishi, M. Feger, M. Bektas, Y. Lembach  
Surprising similarities: neuropsychological impairments assessed by means of a computer-based test in Alzheimer and Multiple Sclerosis patients |
| 2 E      | **Georg Adler**, M. Bektas, Y. Ko-Inoshishi, K. Articus  
Rivastigmine in patients with Parkinson’s disease dementia: short-term neuropsychological and EEG effects |
| 3 I      | **Georg Adler**, M. Bektas, N. Baumgart, Y. Lembach, M. Feger  
Computer-based assessment of memory and attention in patients with Alzheimer’s dementia |
| 4 E      | **Charlotte Ahlgren**, P. Schött, A. Jureus, P. Johnström, A. Takano, S. Nyberg, E. Nordström  
AZD5213, a novel selective histamine H3 receptor antagonist: Receptor occupancy and imaging in rodent and primate brain |
| 5 E      | **Ulrika Akenine**, A. Solomon, N. Andreasen, F. Mangialasche, V. Jelic, M. Kivipelto, B. Winblad  
Title missing |
| 6 B      | **Tom Ala**  
How “reversible” is the dementia that is associated with vitamin B12 deficiency? |
| 7 I      | **Ove Almkvist**, S. Carter, M. Schöll, C. Graff, B. Långström, A. Nordberg  
Episodic memory is associated with PET measures of beta-amyloid, inflammation and glucose metabolism in preclinical and clinical AD |
| 8 A      | **Sandrine Andrieu**, N. Boneva, S. Bineau  
Co-morbidities in Alzheimer’s disease – external validity assessment of clinical trials patients characteristics |
MR imaging features of ARIA (amyloid-related imaging abnormalities) in patients treated with Bapineuzumab |
| 10 G     | **Frederik Barkhof**, M. Daams, M. P. Wattjes, H.R. Brashear, H. M. Arrighi, K. Morris, P. Scheltens  
An MRI grading scale for amyloid-related imaging abnormalities (ARIA) |
The use of the scopolamine challenge model to inform decision making in trials for cognitive efficacy |
Agitation – relation to clinical and dementia biomarkers in cerebrospinal fluid |
Longitudinal stability of biomarkers in cerebrospinal fluid and plasma from patients with Alzheimer’s disease |
<table>
<thead>
<tr>
<th>Category</th>
<th>Authors &amp; Titles [Note: Presenting author is underlined.]</th>
</tr>
</thead>
</table>
CPL204015 inhibits phosphodiesterase 9A activity and improves cognition in rat social recognition model of natural forgetting |
| 15 F     | Simona Capsoni, N. M. Carucci, A. Ferrari, C. Rizzi, A. Cattaneo  
The contribution of early inflammation to neurodegeneration in anti-nerve growth factor mice " |
Summary metrics to assess Alzheimer’s disease-related hypometabolic pattern with FDG-PET: head-to-head comparison |
Phosphodiesterase 7 inhibitor S14 regulates astrocytes-induced degradation of brain amyloid-β |
| 18 D     | Stephen E. Carter, O. Almkvist, A. Nordberg  
Investigating the relationship between disease biomarkers in mild cognitive impairment and Alzheimer’s disease |
Chronic inhibition of the MEK/ERK pathway fails to delay disease progression in a transgenic animal model of tauopathy |
| 20 G     | Seong Choi, S. Kim, D. Na, J. Lee, S. Han, S. Kim, S. Moon, E. Kim, J. Jeong, S. Sse, B. Ku, K. Park  
Impact of white matter changes on conversion from amnestic mild cognitive impairment to dementia |
| 21 H     | Hojin Choi, Hee-Jin Kim, Seong-il Oh, Bek-san Park, Seung Hyun Ha, Hyun-Hee Park, Na-Young Choi, Seong-Ho Koh, Seung Hyun Kim  
Coenzyme Q10 restores Amyloid beta-inhibited proliferation of neural stem cells by activating the PI3K Pathway |
| 22 C     | Hojin Choi, Hee-Jin Kim, Seong-il Oh, Bek-san Park, Seung Hyun Ha, Hyun-Hee Park, Na-Young Choi, Seong-Ho Koh, Seung Hyun Kim  
Sublethal dose of amyloid beta increases the resistance of neural stem cells to ischemic insults |
| 23 H     | Il Han Choo, D. Y. Lee, J. I. Woo  
Difference of amyloid burden increase by APOE genotype in cognitively normal elderly: PIB-PET Study |
| 24 I     | Ivo Cilesi  
Use of the doll with dementia-affected patients with behavior disturbances in a nursing home for Alzheimer patients |
| 25 I     | Ivo Cilesi  
Therapeutic virtual train with dementia-affected patients with behaviour disturbances in a nursing home for Alzheimer patients |
<table>
<thead>
<tr>
<th>Category</th>
<th>Authors &amp; Titles [Note: Presenting author is underlined.]</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 G</td>
<td><strong>Keith S. Cover, R. A. van Schijndel, B. W. van Dijk, A. Redolfi, P. Scheltens, K. L. Knol, G. B. Frisoni, F. Barkhof, H. Vrenken</strong> Reproducibility of brain atrophy measures assessed with ADNI back-to-back MRI scans</td>
</tr>
<tr>
<td>28 E</td>
<td><strong>Jeffrey Cummings, L. Frölich, S. E. Black, S. Bakchine, G. Bellelli, J. L. Molinuevo, R. W. Kressig, P. Downs, A. Caputo, C. Strohmaier</strong> A new option to reach maximum dose efficacy with rivastigmine patch in the treatment of Alzheimer’s disease: results of a 48-week, randomized, double-blind evaluation of the comparative efficacy, safety and tolerability of 9.5 mg/24 h and 13.3 mg/24 h</td>
</tr>
<tr>
<td>30 B</td>
<td><strong>John W. Sijben, P. J. Kamphuis, M. C. de Wilde, R. J. Hageman, L. M. Broersen, M. Groenendijk</strong> Supporting synapse formation and function in Alzheimer’s disease: mechanism of action of the specific nutrient combination Fortasyn™ Connect</td>
</tr>
<tr>
<td>32 A</td>
<td><strong>Ann-Katrin Edlund, K. Spångberg, D. Religa, M. Eriksdotter-Jönhagen, Steering Committee of SveDem Sweden</strong> Quality indicators of dementia care assessed by the national Swedish quality registry on dementia disorders, SveDem</td>
</tr>
<tr>
<td>33 H</td>
<td><strong>Susanna Eketjäll, J. Janson, K. Eliason, P. Appelkvist, A. Radesäter, S. Gustavsson, F. Jeppsson, S. Karlström, K. Kolmodin, J. Fälting</strong> Preclinical evaluation of a novel small molecule BACE1 inhibitor in vivo</td>
</tr>
<tr>
<td>34 G</td>
<td><strong>Daniela Enache, Lena Cavallin, Milica Gregoric Kramberger, Vesna Jelic, F. Göthe, Maria Eriksdotter Jönhagen, Eric Westman, Lars-Olof Wahlund, Bengt Winblad, Dag Aarsland</strong> Medial temporal lobe atrophy in geriatric depression</td>
</tr>
<tr>
<td>36 D</td>
<td><strong>Beata Ferencz, S. Karlsson, E. J. Laukka, G. Kalpouzos, M. Lövden, L. Keller, C. Graff, L. Fratiglioni, L. Bäckman</strong> Mitochondrial biomarkers: The influence of the TOMM40 gene on brain integrity in aging</td>
</tr>
<tr>
<td>Category</td>
<td>Authors &amp; Titles [Note: Presenting author is underlined.]</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 37 F     | Maria Teresa Ferretti, S. Allard, A. Ducatenzeiler, A. C. Cuello  
Abeta-oligomers-induced inflammation in pre-clinical Alzheimer disease as a therapeutic target: evidence from transgenic model |
NPT101 produces rapid and persistent Abeta lowering in aged TG2576 mice |
| 39 G     | Anton Forsberg, Zsolt Cselényi, Anders Juréus, Fredrik Jeppsson, Britt-Marie Swahn, Johan Sandell,  
Maria Eriksdotter Jönhagen, Yvonne Freund-Levi, Per Julin, Magnus Schou, Jan Andersson,  
Peter Johnström, Katarina Varnäs, Christer Halldin, Lars Farde, Samuel Svensson  
| 40 C     | Alexandre Forster, Enikő Kovari, François Herrmann, Panteleimon Giannakopoulos, Constantin Bouras,  
Gabriel Gold  
Cortical microinfarcts in brain aging: no evidence of a relationship with vascular risk factors or concomitant vascular pathology |
| 41 D     | Daniel Frenzel, J. M. Glück, S. Dornieden, S. A. Funke, D. Willbold  
Design and development of an SPR-assay that quantifies the interaction of various Abeta-binding agents with Abeta monomers, oligomers and fibrils |
| 42 G     | M. Boccardi, A. Redolfi, G. Corbetta, D. Tolomeo, P. Pasqualetti, R. Ganzola, N. Robitille, S. Duchesne,  
C. R. Jack, Giovanni B. Frisoni  
Delphi consensus on landmarks for the manual segmentation of the hippocampus on MRI: preliminary results from the EADC-ADNI Harmonized Protocol working group |
Identification of novel synaptic γ-secretase associated proteins and their effect on APP and Notch processing |
| 44 H     | Susanne Aileen Funke, H. Liu, T. Sehl, D. Bartnik, O. Brener, L. Nagel-Steger, D. Willbold  
An amyloid-β binding peptide modulates Aβ oligomerization and is a possible candidate for therapy of Alzheimer’s disease |
| 45 D     | Samantha Galluzzi, C. Geroldi, G. Amicucci, L. Bocchio-Chiavetto, M. Bonetti, C. Bonvicini, M. Cotelli,  
R. Ghidoni, B. Paghera, O. Zanetti, G. B. Frisoni  
Supporting evidence of the AD biomarker dynamic model in patients with mild cognitive impairment |
Structural and molecular imaging of neurodegeneration: a new hybrid PET-MR protocol |
| 47 H     | Biljana Georgievka, S. Gruber, A. Mörtberg, Y. Nilsson, J. Doherty, S. Berg, P. I. Arvidsson, J. Fälting,  
J. Sandin, R. Bhat  
Inhibition of GSK3β improves synaptic function and cognition in mice |
Category | Authors & Titles [Note: Presenting author is underlined.]
--- | ---
Genetic predisposition toward increased oxidative stress as a pathophysiological process implicated in the conversion from Mild Cognitive Impairment to Alzheimer’s disease

49 H | Olof Gissberg, S. Fabre, S. Gruber, P. Arvidsson, B. Georgievksa, A. Mörberg
Acute effect of a glycogen synthase kinase-3 inhibitor on phosphorylated and total tau in P301L transgenic mice

50 H | Tom J. Goldschmidt, S. Eketjäll, K. Tunblad, P. Appelkvist, M. Dabrowski, G. von Euler
The role of alpha 7 agonism for regulation of brain Abeta levels in aged TG2576 APPSWE mice

51 C | Frida Göthe, M. Kramerberger, D. Enache, L. O. Wahlund, E. Westman1, V. Jelic, B. Winblad, D. Aarsland, L. Cavallin
Are white matter lesions correlated to depression in a memory clinic population?

52 H | Stefano Govoni, S. Preda, E. Mura, S. Zappettini, M. Grilli, G. Olivero, M. Marchi
β-amyloid impairs the nicotinic-stimulated neurotransmitter release in rat hippocampus in absence of neurotoxicity

53 E | Nigel H. Greig, Robert E. Becker

54 H | Inge Grundke-Iqbal, S. Bolognin, X. Wang, J. Blanchard, K. Iqbal
Shifting the balance from neurodegeneration to regeneration: A novel therapeutic approach to Alzheimer’s disease

55 C | Göran Hagman, A. Solomon, I. Kåreholt, M. Vuorinen, H. Soininen, M. Kivipelto
Midlife hopelessness and white matter lesions two decades later: a population-based study

56 I | Krister Håkansson, H. Soininen, B. Winblad, A. H. Mohammed, M. Kivipelto
Feelings of hopelessness in midlife are associated with dementia risk in later life

Effects of melatonin on sleep deprivation-induced cognitive impairment

The CSF levels of Aβ42, but not tau, are fully changed already 5-10 years before onset of Alzheimer’s dementia

Biochemical studies of poly-T variants in the Alzheimer disease associated TOMM40 gene

60 A | Erik Hermansson, K. Loganathan, D. Crowther, J. Johansson, J. Presto
Studies of the BRICHOS domain in a Drosophila model – Preventing aggregation of amyloid-like proteins
**Erik Hjorth, H. Eyolfsdottir, M. Schultzberg, M. Eriksdotter**  
Inflammatory signals and maturation of neurotrophins in cerebrospinal fluid of patients with Alzheimer’s disease

**Erik Hjorth, V. Cortés-Toro, M. Schultzberg, D. Aarsland**  
Influence of inflammatory and neurotrophic molecules on depressive symptoms in AD and the relation to disease severity

**Kina Höglund, G. Schevchenko, K. Kultima, S. Musunuri, J. Bergquist, L. Andersson, M. Wetterhall**  
A longitudinal characterization of synaptic markers in the tg2576 amyloid mouse model

**Babak Hooshmand, Sylvia Annerbo, Alina Solomon, Angel Cedazo-Minguez, Johan Lökk, Miia Kivipelto**  
Serum vitamin D in relation to cognitive impairment and CSF biomarkers

**Wen-Chuin Hsu, C. K. J. Shen, K. J. Tsai, M. C. Kuo, C. J. Lin**  
An open-label, no-treatment-controlled, parallel, pilot phase II study to evaluate the efficacy and safety/tolerability profiles of G-CSF in subjects with mild to moderate Alzheimer’s disease: A preliminary report

**Mitsuhiro Inoue, B. Wiehager, J. Y. Hur, B. Winblad, L. Tjernberg**  
The proximity ligation assay shows interaction between novel γ-secretase associated proteins and γ-secretase

**Gerd Faxén Irving, Yvonne Freund-Levi, Maria Eriksdotter-Jönhagen, Hans Basun, Erik Hjorth, Jan Palmblad, Inger Vedin, Tommy Cederholm, Lars-Olof Wahlund**  
Effects of transthyretin in plasma and liquor by DHA-rich n-3 fatty acid supplementation in patients with Alzheimer’s disease

**Ahmet Turan Isik, Gulsen Babacan Yildiz, Ergun Bozoglu, Emine Aydemir**  
Cardiac safety of Donepezil in elderly patients with Alzheimer disease

**Muhammad Al Mustafa Ismail, L. Mateos, C. Graff, I. Björkhem, A. Cedazo-Mínguez**  
Reduced capacity of cholesterol synthesis in Alzheimer’s disease

**M. Florencia Iulita, J. Busciglio, A. C. Cuello**  
Increased proNGF levels in Down syndrome

HPLC-separation of Tau protein fragments for subsequent analysis of immunoreactive domains

In vitro properties of a novel BACE1 inhibitor for the treatment of Alzheimer’s disease

**Ahmadul Kadir, N. Andreasen, O. Almkvist, A. Wall, K. Blennow, B. Längström, H. Zetterberg, A. Nordberg**  
Twelve months Phenserine treatment increased CSF Aβ40 and sAPP levels which correlated with cognitive function, 18F-FDG and 11C-PIB PET in AD patients
<table>
<thead>
<tr>
<th>Category</th>
<th>Authors &amp; Titles [Note: Presenting author is underlined.]</th>
</tr>
</thead>
<tbody>
<tr>
<td>77 I</td>
<td>Hee-jin Kim, Baek San Park, Hojin Choi, Seongil Oh, Seung H. Kim. Characteristics of Behavioral Psychiatric Symptoms of Amyotrophic Lateral Sclerosis with Frontotemporal lobar Degeneration according to the subtypes.</td>
</tr>
<tr>
<td>78 G</td>
<td>Hee-jin Kim, Baek San Park, Seongil Oh, Hojin Choi, Seung H. Kim, Eun-Hyang Song. The relationship between Alzheimer’s pathology and white matter degeneration; Preliminary CSF study.</td>
</tr>
<tr>
<td>79 I</td>
<td>Ilona Hallikainen, Tuomo Hänninen, Kristiina Hongisto, Tärja Välimäki, Mikael S. von und zu Frauberg, Asta Hiltnen, Pertti Karppi, Juhani Sivenius, Hilkka Soininen, Anne M. Koivisto. CERAD-NB total score - a valid method for the follow-up of cognition in patients with Alzheimer’s disease: Kuopio ALSOVA study.</td>
</tr>
<tr>
<td>81 C</td>
<td>Enikö Kövari, G. Gold, F. R. Herrmann, C. Bouras. Cerebral angiopathy and vascular brain pathology: related or not?</td>
</tr>
<tr>
<td>82 G</td>
<td>Bon Ku, J. S. Kim, H. Y. Rhee, K. C. Park. The longitudinal cognitive impact of the white matter hyperintensities to the patients with mild to moderate Alzheimer’s disease.</td>
</tr>
<tr>
<td>Category</td>
<td>Authors &amp; Titles [Note: Presenting author is underlined.]</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>86 I</td>
<td>G.T.H. Wong, S. Wuwongse, R.C.C. Chang, Andrew C.K. Law</td>
</tr>
<tr>
<td></td>
<td>Synaptic and cytoskeletal changes in Alzheimer’s disease and depression</td>
</tr>
<tr>
<td>87 C</td>
<td>Jun Hong Lee, S. J. Shin, H.J. Hong, H. S. Yoo</td>
</tr>
<tr>
<td></td>
<td>Clinical factors related to intracranial arterial stenosis in stroke patients with Alzheimer disease</td>
</tr>
<tr>
<td>88 E</td>
<td>Anna M. Lilja, S. Callender, E. Yoo, A. Nordberg, A. Marutle</td>
</tr>
<tr>
<td></td>
<td>α7 nAChR agonists and amyloid-modulatory drugs are potent stimulators of neurogenesis in progenitor cells exposed to human Aβ oligomer assemblies</td>
</tr>
<tr>
<td>89 A</td>
<td>Ann-Marie Liljeroth, C. Collijn</td>
</tr>
<tr>
<td></td>
<td>Swedish Dementia Registry as a tool of quality in the chain of care of dementia diseases</td>
</tr>
<tr>
<td>90 A</td>
<td>Anders Lonneborg, G. Grave, L. Kristiansen, T. Lindahl, L. Roed, M. Sjogren, E. Rian, P. Sharma</td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease biology of a 96 gene expression assay developed to aid in the diagnosis of the disease</td>
</tr>
<tr>
<td>91 D</td>
<td>Marco Lorenzi, G. Frisoni, N. Ayache, X. Pennec</td>
</tr>
<tr>
<td></td>
<td>Effects of abnormal CSF Aβ42 values on the longitudinal atrophy in healthy elders</td>
</tr>
<tr>
<td>92 H</td>
<td>Johan Lundkvist, C. Dahlqvist, F. Olsson, J. Parkinson, S. Visser</td>
</tr>
<tr>
<td></td>
<td>A review and analysis of γ-secretase inhibitor trials; has Aβ production inhibition been adequately validated as therapeutic approach in mild AD?</td>
</tr>
<tr>
<td>93 I</td>
<td>Dulce Maia, P. Pimentel, S. Nunes, M. Silva</td>
</tr>
<tr>
<td></td>
<td>Neuropsychological assessment in diagnosis of Dementia</td>
</tr>
<tr>
<td>94 B</td>
<td>Silvia Maioli, E. Puerta, P. Merino-Serrais, F. Gil-Bea, R. Rimondini, A. Cedazo-Minguez</td>
</tr>
<tr>
<td></td>
<td>Interaction between ApoE4 genotype and a high carbohydrate diet in Alzheimer Disease</td>
</tr>
<tr>
<td>95 B</td>
<td>Francesca Mangialasche, E. Westman, M. Kivipelto, J. S. Muehlboeck, R. Cecchetti, M. Baglioni, H. Soininen, I. Koszewska, M. Tsalaki, B. Vellas, C. Spencer, S. Lovestone, L-O Wahlund, A. Simmons, P. Mecocci</td>
</tr>
<tr>
<td></td>
<td>Classification and prediction of clinical Alzheimer’s diagnosis based on MRI and plasma vitamin E measures</td>
</tr>
<tr>
<td>96 E</td>
<td>Paul Maruff, A. Fredrickson, J. Gale, P. Snyder</td>
</tr>
<tr>
<td></td>
<td>A real-time system for monitoring cognitive safety in clinical trials of disease modifying compounds</td>
</tr>
<tr>
<td></td>
<td>Determining rate of decline in amyloid positive pre-AD AIBL participants using regular brief cognitive assessments</td>
</tr>
<tr>
<td></td>
<td>Effect of Aβ burden and apolipoprotein E genotype on cognitive decline at 18 months in healthy older adults</td>
</tr>
<tr>
<td>Category</td>
<td>Authors &amp; Titles [Note: Presenting author is underlined.]</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Influence of ApoE genotype on amyloid PET-ligand binding and correlation to pathology in human post mortem brain tissue</td>
</tr>
<tr>
<td></td>
<td>CSF Aβ isoforms as novel pharmacodynamic markers of BACE1 inhibition</td>
</tr>
<tr>
<td>101 H</td>
<td>Giovanni Meli, Agnese Lecci, Nina Krako, Annalisa Manca, Valentina Albertini, Luisa Benussi, Roberta Ghidoni, Antonino Cattaneo</td>
</tr>
<tr>
<td></td>
<td>Subcellular targeting of Aβ oligomers with conformational intrabodies</td>
</tr>
<tr>
<td>102 I</td>
<td>Aline Mendes, L. Mieiro, C. E. Graf, S. Giannelli, P. Gattelet, Y. Registe-Rameau, F. R. Herrmann, G. Gol, D. Zekry</td>
</tr>
<tr>
<td></td>
<td>Use of physical restraints in hospitalized elderly: experience with severely demented patients</td>
</tr>
<tr>
<td>103 I</td>
<td>Pascal Missonnier, F. R. Herrmann, J. Richardi, C. Rodriguez, M-P Deiber, G. Gold, P. Giannakopoulos</td>
</tr>
<tr>
<td></td>
<td>Attention-related potentials allow for a highly accurate discrimination of MCI subtypes</td>
</tr>
<tr>
<td>104 E</td>
<td>José L. Molinuevo, O. Lemming, D. Wilkinson</td>
</tr>
<tr>
<td></td>
<td>Effects of memantine in patients with moderate Alzheimer’s disease receiving stable doses of Donepezil</td>
</tr>
<tr>
<td>105 H</td>
<td>Anette Mörtberg, E. Floby, S. Fabre, B. Georgievskaja, P. Arvidsson</td>
</tr>
<tr>
<td></td>
<td>Characterization of the young rat model with regards to effects on hippocampal Tau phosphorylation</td>
</tr>
<tr>
<td>106 G</td>
<td>Miguel Ángel Muñoz Ruiz, P. Hartikainen, J. Koikkalainen, R. Wolz, V. Julkunen, E. Niskanen, S-K Herukka, M. Kivipelto, R. Vanninen, D. Rueckert, J Lötjönen, H. Soininen</td>
</tr>
<tr>
<td></td>
<td>Frontotemporal dementia multimodal MRI study.</td>
</tr>
<tr>
<td>107 H</td>
<td>M. Wolff, O. Brener, C. Decker, Luitgard Nagel-Steger, D. Willbold</td>
</tr>
<tr>
<td></td>
<td>Early aggregates in the self-assembly process of the amyloid β peptide</td>
</tr>
<tr>
<td>108 G</td>
<td>Ruiqing Ni, A. Marutle, P. Gillberg, A. Nordberg</td>
</tr>
<tr>
<td></td>
<td>Characterization of PET amyloid tracers in autopsy Alzheimer brain</td>
</tr>
<tr>
<td>109 H</td>
<td>Annelie Pamrén, L. Hedskog, A. Berling, M. Ankarcrona, H. Karlström</td>
</tr>
<tr>
<td></td>
<td>The role of Aph-1 homologues for APP and Notch processing</td>
</tr>
<tr>
<td>110 D</td>
<td>Josef Pannee, J. Gobom, M. Oppermann, A. Atkins, H. Zetterberg, L. Minthon, O. Hansson, K. Blennow, E. Portelius</td>
</tr>
<tr>
<td></td>
<td>An LC-MS/MS-based method for quantification of Aβ1-38, Aβ1-40 and Aβ1-42 in CSF of AD patients and healthy controls</td>
</tr>
<tr>
<td></td>
<td>Sleep problems are associated with behavioral symptoms as well as cognitive functions in dementia patients</td>
</tr>
<tr>
<td>Category</td>
<td>Authors &amp; Titles [Note: Presenting author is underlined.]</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 112 E    | Byeong C Kim, Kyung Won Park, Hyun Jeong Han, Seong Hye Choi, Kee Kyung Park  
Effect of Apolipoprotein E genotype on response to rivastigmine transdermal patch or memantine add-on therapy in patients with Alzheimer’s disease |
| 113 E    | C. Balla, Jean Louis Pepin, A. Maertens de Noordhout  
Pharmacological manipulation of cholinergic pathways affects the threshold for motor cortex magnetic stimulation in Alzheimer’s disease |
| 114 H    | Torbjörn Persson, F. Lattanzio, L. Mateos-Montejo, M. Rubio-Rodrigo, A. Sandebring, A. Cedazo-Minguez  
ApoE4 compromises Thioredoxin 1 (TRX1) levels in brain, activating the apoptosis signaling cascade |
| 115 F    | Elena Puerta, M. Lodeiro, L. Mateos, S. Maioli, M. Rubio, A. Cedazo-Minguez  
Hypercholesterolemia-mediated increase of S100A8 and RAGE in brain: a molecular link with neuroinflammation and Alzheimer’s disease |
| 116 G    | Alberto Redolfi, Gabriele Corbeta, David Manset, Jerome Revillard, Baptiste Grenier, Giovanni B. Frisoni  
Cortical thinning in ADNI patients: how good is automated reconstruction? |
| 117 G    | Irena Rektorova, L. Krajcovicova, R. Marecek, M. Mikl  
Default mode network connectivity in Alzheimer’s disease and Parkinson’s disease dementia |
| 118 A    | Dorota Religa, K. Spångberg, A. Wimo, A. K. Eklund, B. Winblad, M. Eriksdotter  
Dementia diagnosis differs in men and women and depends on age and dementia severity. Data from SveDem, the Swedish Dementia Registry |
| 119 E    | Dorota Religa, K. Johnell, M. Eriksdotter  
Dementia drug treatment in clinical reality, a nationwide study of 7570 patients from SveDem, Swedish Dementia Registry |
| 120 E    | Jan Ricny, Z Kristofikova, J Korabecny, K Kuca, K Musilek, J Proska  
Title missing |
| 121 E    | S. Black, S. Cohen, S. Gauthier, M. Hubert, R. Schecter, F. deTakacsy, B. Rehel, Alain Robillard  
Results of the EMBRACE Canadian study evaluating Rivastigmine Patch in patients with Alzheimer disease during an 18-month follow-up |
| 122 A    | Line Roed, T. Lindahl, G. Grave, E. Rian, M. Sjögren, P. Sharma, A Lönneborg  
Development of blood-based gene expression tests for identification of prodromal AD and rate of progression of AD |
| 123 D    | Jennie Röjdner, R. Ni, A. Thiele, T. Dyrks, A. Marutle, A. Nordberg  
Studies of amyloid and neuroinflammatory markers in Alzheimer autopsy brain regions using a multi-tracer concept |
| 124 F    | Arvid Rongve, Dag Aarsland  
Cytokines and depression in Alzheimer’s disease — is there a connection? |
### Category: **Authors & Titles [Note: Presenting author is underlined.]**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>125 H</td>
<td>Mitochondrial function in a transgenic mouse model expressing human APP with the Arctic mutation</td>
<td><strong>Annica Rönnbäck</strong>, B. Winblad, C. Graff, H. Behbahani</td>
</tr>
<tr>
<td>128 D</td>
<td>Aβ43 can be detected by ELISA in soluble, SDS-soluble and detergent resistant fractions from human brain</td>
<td><strong>Anna Sandebring</strong>, H. Welander, B. Winblad, C. Graff, L. O. Tjernberg</td>
</tr>
<tr>
<td>130 H</td>
<td>γ-Secretase inhibitor treatment results in impaired behavior in the contextual fear conditioning test in the mouse</td>
<td><strong>Johan Lundkvist</strong>, Pär Schött, Rebeca Klingtenberg, Susanne Gruber, Paulina Appelkvist, Kia Strömberg, Per Arvidsson, Biljana Georgievska, Johan Sandin</td>
</tr>
<tr>
<td>131 F</td>
<td>The effects of airway associated inflammation on behaviour in 3xTgAD mice</td>
<td><strong>Heela Sarlus</strong>, A. Codita, X. Wang, B. Winblad, M. Schultzberg, M. Oprica</td>
</tr>
<tr>
<td>134 H</td>
<td>Studies of the interaction between gamma-secretase and NDUFS7 with in situ proximity ligase assay</td>
<td><strong>Sophia Schedin Weiss</strong>, M. Inoue, S. Frykman, Y. Teranishi, B. Winblad, L. Tjernberg</td>
</tr>
<tr>
<td>135 G</td>
<td>Low PIB PET retention in the presence of pathological other AD biomarkers in Arctic APP mutation carriers</td>
<td><strong>Michael Schöll</strong>, A. Wall, S. Thordardottir, D. Ferreira, N. Bogdanovic, B. Långström, O. Almkvist, C. Graff, A. Nordberg</td>
</tr>
</tbody>
</table>
12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy

**Category**

**Authors & Titles [Note: Presenting author is underlined.]**

**137 I** Joon Hyun Shin, E. A. Oh, B. G. Yeon, Dong Sok Shim
Neuropsychological Differences between Apolipoprotein E4 positive and negative subgroups in Alzheimer’s Disease

**138 B** S. Lopes da Silva, S. Elemans, P. Kamphuis, John W. C. Sijben, M. Groenendijk
Plasma nutrient status of Alzheimer’s disease patients compared to cognitive intact elderly controls: a systematic review and meta-analysis

**139 B** N. van Wijk, M. Balvers, R. J. J. Hageman, John W. C. Sijben, P. J. G. H. Kamphuis, L. M. Broersen
Dose-dependent effects of dietary folate, vitamin B12 and vitamin B6 on plasma lipid profile in rats

**140 I** Maja Smrdu, M. Gregoric Kramberger, J. Jensterle, M. Trost, Z. Pirtosek
Relationship between cognitive screening results and measure of episodic memory in early Alzheimer's disease

**141 E** Ondrej Soukup, J. Patocka, J. Zdarova-Karasova, D. Jun, K. Kuca
The tacrine derivative 7-MEOTA in the treatment of AD

**142 G** Gabriela Spulber, J. S. Muehlboeck, P. Mecocci, B. Vellas, M. Tsolaski, I. Kjoszewska, H Soininen, C. Spenger, S. Lovestone, A. Simmons, L. O. Wahlund, E. Westman
A MR based atrophy index measuring the severity of Alzheimer’s disease-like pathology in predementia cases

**143 A** Elka Stefanova, I. Despotovic, T. Stojkovic, M. Jecmenica Lukic, S. Radojevic
The demographic and clinical data of dementia patients from the Belgrade Memory clinic- 3 year experience

**144 D** Elisabeth Steinhagen-Thiessen, M. Bimmler, C. Jonatat, U. Kassner, I. Decius, B. Heinig, P. Hempel, P. Rosenthal, P. Karczewski, R. Kunze
Immunoaosorption (IA) of autoantibodies (AAB) against adrenoceptors (AR) in patients with Alzheimer disease/Alzheimer disease with vascular component (AD/VD)

**145 H** Joanna Stepek, E. Gospodarska, M. Kulma, M. Dadlez
Aβ16-23’ peptide – a potential inhibitor of RAGE-dependent Aβ40 endocytosis in bEnd.3 cells

**146 H** L. Dahllund, D. Malinowsky, F. Olsson, M. Berg, C. Raynoschek, A. C. Radesäter, M. Dabrowski, Kia Strömberg
GSAP - a therapeutic target for Alzheimer’s disease?

**147 E** Kajsa Stubendorff, Victoria Larsson, Lennart Minthon, Elisabet Londos
Does responding to treatment with memantine predict survival in dementia with Lewy bodies and Parkinson's disease with dementia?

**148 H** Karen L. Sundell, D. B. Henley, G. Sethuraman, E. R. Siemers
Safety profile of 1054 placebo treated Alzheimer’s disease patients during the IDENTITY studies

MARK2 and Tau frequently interact in pSer262-immunopositive neurons of Alzheimer’s disease brain revealed by proximity ligation
**Category**  
**Authors & Titles [Note: Presenting author is underlined.]**

150 H  
**Barbara Tate, Robyn B. Loureiro, Timothy D. McKee, JoAnn Dumin, Vladislav Zarayskiy, Wesley F. Austin, Nathan O. Fuller, Jed L. Hubbs, Ruichao Shen, Jeffrey Ives, Jeff Jonker, Brian Bronk**  
A novel, potent, and selective modulator of gamma secretase

151 H  
**Volkmar Tell, M. Holzer, L. Herrmann, B. Voigt, K. Wichapong, Ch. Schächtele, F. Totzke, W. Sippl, A. Hilgeroth**  
Pharmacological evaluation of novel highly active AD-relevant protein kinase inhibitors

152 D  
**Steinunn Thordardottir, A. Kinhult-Ståhlbom, K. Blennow, O. Almkvist, N. Andreasen, M. Eriksdotter, C. Graff**  
Cerebrospinal fluid biomarkers in mutation carriers with preclinical familial Alzheimer disease: Comparison with healthy family members

153 I  
**Gustav Torisson, L. Minthon, L. Stavenow, E. Londos**  
Cognitive and performance-based functional measures predicting mortality in elderly medical inpatients

154 I  
**Eduardo Torrealba, P. Garcia-Morales, J. C. Cejudo, N. Gramunt, F. Sánchez-García, O. Fabre-Pi**  
InOut Test: Diagnosis of potential converters from Mild Cognitive Impairment (MCI) and Subjective Memory Complaints (SMC) to dementia by a new cognitive paradigm

155 G  
**M. G. Kramberger, P. Tomše, M. Grmek, Z. Pirtošek, Maja Trošt**  
Brain perfusion changes in patients with Alzheimer’s disease and dementia with Lewy bodies

156 A  
**Christina Unger Lithner, T. Mustafiz, A. Nordberg, J. D. Sweatt, C. M. Hernandez**  
Epigenetics in Alzheimer’s Disease - changes related to Aβ

157 H  
**Ann Van der Jeugd, A. Lo, K. Belarbi, M. Hamdame, D. Blum L. Buée, R. D’Hooge**  
Behavioural effects of selenium in mouse models of Alzheimer’s disease

158 D  
**Swetha Vijayaraghavan, Walter Maetzler, Matthias Reimold, Christina Unger Lithner, Inga Liepelt, Daniela Berg, Taher Darreh-Shori**  
High apolipoprotein E in cerebrospinal fluid associated with neuroimaging and neurodegenerative parameters in Lewy body-associated dementia disorders

159 H  
**Gabriel von Euler, H. Lund, M. Nilsson, A. Svensson, M. Berg, E. Gustafsson, D. Sunnemark**  
Expression of MARK1, 2, 3, and 4 in AD brain

160 E  
**Larysa Voytenko, A. Marutle, A. Nordberg**  
Immunohistochemical characterization of β-amyloid plaques, activated astrocytes and α7 nicotinic receptors in AD autopsy brain

161 D  
**Åsa K. Wallin, C. Wattmo, L. Minthon**  
Alzheimer’s disease with normal CSF biomarkers

162 F  
**Xiuzhe Wang, E. Hjorth, E. Puerta, L. Orejana, A. Cedazo-Minguez, M. Schultzberg**  
Disturbance of resolution stage of inflammation in SAMP8 Mice
12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy

Posters 2012

Category Authors & Titles [Note: Presenting author is underlined.]

Impact of different γ-secretase modulators on Notch-1 Abeta-like peptide (Nβ) formation

Association study of NEDD9 in Parkinson’s and Alzheimer’s disease

165 G Eric Westman, J-S Muehlboeck, A. Simmons
Combining MRI and CSF measures for classification of Alzheimer’s disease and prediction of mild cognitive impairment conversion

166 B Y. Freund-Levi, P. J. Visser, M. Kivipelto, Rico L. Wieggers, T. Hartmann, H. Soininen
The LipiDiDiet study: rationale and study design

167 B P. Scheltens, R. Shah, D. Bennett, Rico Wieggers, T. Hartmann, H. Soininen, P. J. Kamphuis
The Souvenaid™ clinical trial program for Alzheimer’s disease

Modern network technology to study brain networks, as illustrated by a study with a medical food in patients with Alzheimer’s disease

169 H D. Bartnik, T. van Groen, I. Kadish, O. Brener, L. Nagel-Steger, AHC Horn, H. Sticht, S. A. Funke, Dieter Willbold
The Aβ-oligomer targeting D-peptide D3 is efficiently improving pathology and cognition of orally treated transgenic AD mice

170 E Bengt Winblad, L. Seely, A. Langenberg, D. Forer, B. Selby, the International CONCERT Study Team, Medivation, Inc.
The CONCERT Study: Results of a 12-month, placebo-controlled, parallel group trial in patients with mild-to-moderate Alzheimer’s disease on stable background therapy with Donepezil

171 G Bora Yoon, Yong S. Shim, Kee Ook Lee, Yong-Duk Kim, Sang-Jun Na
The effects of white matter hyperintensities on cognitive impairment in patients with amnestic mild cognitive impairment

172 G Maria Cotelli, R. Manenti, A. Alberici, M Brambilla, M Cosseddu, O. Zanetti, A. Miozzo, A. Padovani, C. Miniussi, B. Borroni
Prefrontal cortex rTMS enhances action naming in progressive non-fluent aphasia

173 F Mingjin Zhu, Erik Hjorth, Marianne Schultzberg
Resolution of inflammation in Alzheimer’s Disease – a new therapeutic strategy

38
A DIAGNOSIS – EPIDEMIOLOGY – GENETICS
Abstracts 8, 32, 48, 59, 60, 89, 90, 118, 122, 143, 156, 164

Co-morbidities in Alzheimer’s disease – external validity assessment of clinical trials patients characteristics [Sandrine Andrieu, Abstract #8]

Quality indicators of dementia care assessed by the national Swedish quality registry on dementia disorders, SveDem [Ann-Katrin Edlund, Abstract #32]

Genetic predisposition toward increased oxidative stress as a pathophysiological process implicated in the conversion from Mild Cognitive Impairment to Alzheimer’s disease [Sandra V. Giannelli, Abstract #48]

Biochemical studies of poly-T variants in the Alzheimer disease associated TOMM40 gene [Louise Hedskok, Abstract #59]

Studies of the BRICHOS domain in a Drosophila model – Preventing aggregation of amyloid-like proteins [Erik Hermansson, Abstract #60]

Swedish Dementia Registry as a tool of quality in the chain of care of dementia diseases [Ann-Marie Liljeroth, Abstract #89]

Alzheimer’s disease biology of a 96 gene expression assay developed to aid in the diagnosis of the disease [Anders Lonneborg, Abstract #90]

Dementia diagnosis differs in men and women and depends on age and dementia severity. Data from SveDem, the Swedish Dementia Registry [Dorota Religa, Abstract #118]

Development of blood-based gene expression tests for identification of prodromal AD and rate of progression of AD [Line Roed, Abstract #122]

The demographic and clinical data of dementia patients from the Belgrade Memory clinic- 3 year experience [Elka Stefanova, Abstract #143]

Epigenetics in Alzheimer’s Disease - changes related to Aβ [Christina Unger Lithner, Abstract #156]

Association study of NEDD9 in Parkinson’s and Alzheimer’s disease [Mimi Marie Westerlund, Abstract #164]

B NUTRITION – CHOLESTEROL – VITAMINS
Abstracts 6, 30, 64, 67, 69, 94, 95, 132, 133, 138, 139, 166, 167, 168

How “reversible” is the dementia that is associated with vitamin B12 deficiency? [Tom Ala, Abstract #6]

Supporting synapse formation and function in Alzheimer’s disease: mechanism of action of the specific nutrient combination Fortasyn™ Connect [John W. Sijben, Abstract #30]
Serum vitamin D in relation to cognitive impairment and CSF biomarkers
[Babak Hooshmand, Abstract #64]

Effects of transthyretin in plasma and liquor by DHA-rich n-3 fatty acid supplementation in patients with Alzheimer’s disease [Gerd Faxén Irving, Abstract #67]

Reduced capacity of cholesterol synthesis in Alzheimer’s disease
[Muhammad Al Mustafa Ismail, Abstract #69]

Interaction between ApoE4 genotype and a high carbohydrate diet in Alzheimer Disease
[Silvia Maioli, Abstract #94]

Classification and prediction of clinical Alzheimer’s diagnosis based on MRI and plasma vitamin E measures [Francesca Mangialasche, Abstract #95]

Combined nutrient enrichment induces changes in synaptic protein expression in vitro
[Paul J. Savelkoul, Abstract #132]

Nutritional intervention with Fortasyn Connect: beneficial effects in experimental models of Alzheimer’s pathology and functional decline [Paul J. Savelkoul, Abstract #133]

Plasma nutrient status of Alzheimer’s disease patients compared to cognitive intact elderly controls: a systematic review and meta-analysis [John W. C. Sijben, Abstract #138]

Dose-dependent effects of dietary folate, vitamin B12 and vitamin B6 on plasma lipid profile in rats [John W. C. Sijben, Abstract #139]

The LipiDiDiet study: rationale and study design [Rico L. Wieggers, Abstract #166]

The Souvenaid® clinical trial program for Alzheimer’s disease [Rico L. Wieggers, Abstract #167]

Modern network technology to study brain networks, as illustrated by a study with a medical food in patients with Alzheimer’s disease [Rico L. Wieggers, Abstract #168]

Sublethal dose of amyloid beta increases the resistance of neural stem cells to ischemic insults
[Hojin Choi, Abstract #22]

Cortical microinfarcts in brain aging: no evidence of a relationship with vascular risk factors or concomitant vascular pathology [Alexandre Forster, Abstract #40]

Are white matter lesions correlated to depression in a memory clinic population?
[Frida Göthe, Abstract #51]
C

VASCULAR (continued)

Midlife hopelessness and white matter lesions two decades later: a population-based study [Göran Hagman, Abstract #55]

Cerebral angiopathy and vascular brain pathology: related or not? [Enikö Kövari, Abstract #81]

Agonistic autoantibodies against the α1-adrenoceptor in patients with Morbus Alzheimer and vascular dementia [Rudolf Kunze, Abstract #84]

Clinical factors related to intracranial arterial stenosis in stroke patients with Alzheimer disease [Jun Hong Lee, Abstract #87]

D

BIOMARKERS

Abstracts 12, 13, 17, 18, 29, 36, 41, 45, 58, 71, 74, 91, 100, 110, 123, 128, 144, 152, 158, 161

Agitation – relation to clinical and dementia biomarkers in cerebrospinal fluid [Victor Bloniecki, Abstract #12]

Longitudinal stability of biomarkers in cerebrospinal fluid and plasma from patients with Alzheimer’s disease [Anna Bogstedt, Abstract #13]

Phosphodiesterase 7 inhibitor S14 regulates astrocytes-induced degradation of brain amyloid-β [Eva Carro, Abstract #17]

Investigating the relationship between disease biomarkers in mild cognitive impairment and Alzheimer’s disease [Stephen F. Carter, Abstract #18]

Evaluation of molecular processes related to synaptopathy in cerebrospinal fluid: SNAP25 and neurogranin as markers of pre- and post-synaptic integrity [Eugeen Vanmechelen, Abstract #29]

Mitochondrial biomarkers: The influence of the TOMM40 gene on brain integrity in aging [Beata Ferencz, Abstract #36]

Design and development of an SPR-assay that quantifies the interaction of various Abeta-binding agents with Abeta monomers, oligomers and fibrils [Daniel Frenzel, Abstract #41]

Supporting evidence of the AD biomarker dynamic model in patients with mild cognitive impairment [Samantha Galluzzi, Abstract #45]

The CSF levels of Aβ42, but not tau, are fully changed already 5-10 years before onset of Alzheimer’s dementia [Oskar Hansson, Abstract #58]

HPLC-separation of Tau protein fragments for subsequent analysis of immunoreactive domains [Barbora Jankovicova, Abstract #71]

Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer’s disease [Azadeh Karami, Abstract #74]
<table>
<thead>
<tr>
<th>Category</th>
<th>Category Description &amp; Poster Titles [Note: Presenting author only is listed]</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
<td><strong>BIOMARKERS</strong> (continued)</td>
</tr>
<tr>
<td></td>
<td>Effects of abnormal CSF Aβ42 values on the longitudinal atrophy in healthy elders [Marco Lorenzi, Abstract #91]</td>
</tr>
<tr>
<td></td>
<td>CSF Aβ isoforms as novel pharmacodynamic markers of BACE1 inhibition  [Niklas Mattsson, Abstract #100]</td>
</tr>
<tr>
<td></td>
<td>An LC-MS/MS-based method for quantification of Aβ1-38, Aβ1-40 and Aβ1-42 in CSF of AD patients and healthy controls  [Josef Pannee, Abstract #110]</td>
</tr>
<tr>
<td></td>
<td>Studies of amyloid and neuroinflammatory markers in Alzheimer autopsy brain regions using a multi-tracer concept [Jennie Röjdner, Abstract #123]</td>
</tr>
<tr>
<td></td>
<td>Aβ43 can be detected by ELISA in soluble, SDS-soluble and detergent resistant fractions from human brain [Anna Sandebring, Abstract #128]</td>
</tr>
<tr>
<td></td>
<td>Immunoabsorption (IA) of autoantibodies (AAB) against adrenoceptors (AR) in patients with Alzheimer disease/Alzheimer disease with vascular component (AD/VD) [Elisabeth Steinhagen-Thiessen, Abstract #144]</td>
</tr>
<tr>
<td></td>
<td>Cerebrospinal fluid biomarkers in mutation carriers with preclinical familial Alzheimer disease: Comparison with healthy family members [Steinunn Thordardottir, Abstract #152]</td>
</tr>
<tr>
<td></td>
<td>High apolipoprotein E in cerebrospinal fluid associated with neuroimaging and neurodegenerative parameters in Lewy body-associated dementia disorders [Swetha Vijayaraghavan, Abstract #158]</td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease with normal CSF biomarkers [Åsa K. Wallin, Abstract #161]</td>
</tr>
<tr>
<td>E</td>
<td><strong>CHOLINESTERASE INHIBITORS – CHOLINERGIC – MEMANTINE – TREATMENT</strong></td>
</tr>
<tr>
<td></td>
<td>Rivastigmine in patients with Parkinson’s disease dementia: short-term neuropsychological and EEG effects [Georg Adler, Abstract #2]</td>
</tr>
<tr>
<td></td>
<td>AZD5213, a novel selective histamine H3 receptor antagonist: Receptor occupancy and imaging in rodent and primate brain [Charlotte Ahlgren, Abstract #4]</td>
</tr>
<tr>
<td></td>
<td>Title missing [Ulrika Akenine, Abstract #5]</td>
</tr>
<tr>
<td></td>
<td>The use of the scopolamine challenge model to inform decision making in trials for cognitive efficacy [Joanne Bell, Abstract #11]</td>
</tr>
<tr>
<td></td>
<td>CPL204015 inhibits phosphodiesterase 9A activity and improves cognition in rat social recognition model of natural forgetting [Lukasz Bojarski, Abstract #14]</td>
</tr>
<tr>
<td></td>
<td>Cognitive and molecular effects of AVCRI104P3, a multitarget anti-Alzheimer drug candidate, in 3XTG-AD mice [M. Victoria Clos, Abstract #26]</td>
</tr>
</tbody>
</table>
A new option to reach maximum dose efficacy with rivastigmine patch in the treatment of Alzheimer’s disease: results of a 48-week, randomized, double-blind evaluation of the comparative efficacy, safety and tolerability of 9.5 mg/24 h and 13.3 mg/24 h [Jeffrey Cummings, Abstract #28]

Expression and characterization of an Aβ binding single-chain variable fragment – a novel tool for the treatment of Alzheimer’s disease? [Silke Dornieden, Abstract #31]

EEG changes during cell therapy with nerve growth factor in Alzheimer’s disease: relation to cholinergic markers and neuropsychology [Helga Eyjófsdóttir, Abstract #35]


An open-label, no-treatment-controlled, parallel, pilot phase II study to evaluate the efficacy and safety/tolerability profiles of G-CSF in subjects with mild to moderate Alzheimer’s disease: A preliminary report [Wen-Chuin Hsu, Abstract #65]

Cardiac safety of Donepezil in elderly patients with Alzheimer disease [Ahmet Turan Isik, Abstract #68]

Increased proNGF levels in Down syndrome [M. Florencia Iulita, Abstract #70]

Twelve months Phenserine treatment increased CSF Aβ40 and sAPP levels which correlated with cognitive function, 18F-FDG and 11C-PIB PET in AD patients [Ahmadul Kadir, Abstract #73]

Synthesis, biological assessment and molecular modeling of novel tacrine-7 methoxytacrine heterodimers for Alzheimer disease treatment [Jan Korabecny, Abstract #80]

α7 nAChR agonists and amyloid-modulatory drugs are potent stimulators of neurogenesis in progenitor cells exposed to human Aβ oligomer assemblies [Anna M. Lilja, Abstract #88]

A real-time system for monitoring cognitive safety in clinical trials of disease modifying compounds [Paul Maruff, Abstract #96]

Effects of memantine in patients with moderate Alzheimer’s disease receiving stable doses of Donepezil [José L. Molinuevo, Abstract #104]

Effect of Apolipoprotein E genotype on response to rivastigmine transdermal patch or memantine add-on therapy in patients with Alzheimer’s disease [Kyung Won Park, Abstract #112]

Pharmacological manipulation of cholinergic pathways affects the threshold for motor cortex magnetic stimulation in Alzheimer’s disease [Jean Louis Pepin, Abstract #113]

Dementia drug treatment in clinical reality, a nationwide study of 7570 patients from SveDem, Swedish Dementia Registry [Dorota Religa, Abstract #119]
E CHOLINESTERASE INHIBITORS – CHOLINERGIC – MEMANTINE – TREATMENT

Title missing [Jan Ricny, Abstract #120]

Results of the EMBRACE Canadian study evaluating Rivastigmine Patch in patients with Alzheimer disease during an 18-month follow-up [Alain Robillard, Abstract #121]


AZD5213, a novel selective H3 receptor antagonist. Effect on neurotransmitter release and cognitive performance in rodents [Pär Schött, Abstract #136]

The tacrine derivative 7-MEOTA in the treatment of AD [Ondrej Soukup, Abstract #141]

Does responding to treatment with memantine predict survival in dementia with Lewy bodies and Parkinson’s disease with dementia? [Kajsa Stubendorff, Abstract #147]

Immunohistochemical characterization of β-amyloid plaques, activated astrocytes and α7 nicotinic receptors in AD autopsy brain [Larysa Voytenko, Abstract #160]

The CONCERT Study: Results of a 12-month, placebo-controlled, parallel group trial in patients with mild-to-moderate Alzheimer’s disease on stable background therapy with Donepezil [Bengt Winblad, Abstract #170]

F INFLAMMATION

Abstracts 15, 37, 61, 62, 115, 124, 131, 162, 173

The contribution of early inflammation to neurodegeneration in anti-nerve growth factor mice [Simona Capsoni, Abstract #15]

Abeta-oligomers-induced inflammation in pre-clinical Alzheimer disease as a therapeutic target: evidence from transgenic model [Maria Teresa Ferretti, Abstract #37]

Inflammatory signals and maturation of neurotrophins in cerebrospinal fluid of patients with Alzheimer’s disease [Erik Hjorth, Abstract #61]

Influence of inflammatory and neurotrophic molecules on depressive symptoms in AD and the relation to disease severity [Erik Hjorth, Abstract #62]

Hypercholesterolemia-mediated increase of S100A8 and RAGE in brain: a molecular link with neuroinflammation and Alzheimer’s disease [Elena Puerta, Abstract #115]

Cytokines and depression in Alzheimer’s disease — is there a connection? [Arvid Rongve, Abstract #124]

The effects of airway associated inflammation on behaviour in 3xTgAD mice [Heela Sarlus, Abstract #131]
Disturbance of resolution stage of inflammation in SAMP8 Mice [Xiuze Wang, Abstract #162]

Resolution of inflammation in Alzheimer’s Disease – a new therapeutic strategy
[Mingqin Zhu, Abstract #173]

MR imaging features of ARIA (amyloid-related imaging abnormalities) in patients treated with Bapineuzumab [Jerome Barakos, Abstract #9]

An MRI grading scale for amyloid-related imaging abnormalities (ARIA) [Frederik Barkhof, Abstract #10]

Summary metrics to assess Alzheimer’s disease-related hypometabolic pattern with FDGPET: head-to-head comparison [Anna Caroli, Abstract #16]

Impact of white matter changes on conversion from amnestic mild cognitive impairment to dementia [Seong Choi, Abstract #20]

Reproducibility of brain atrophy measures assessed with ADNI back-to-back MRI scans [Keith S. Cover, Abstract #27]

Medial temporal lobe atrophy in geriatric depression [Daniela Enache, Abstract #34]


Delphi consensus on landmarks for the manual segmentation of the hippocampus on MRI: preliminary results from the EADC-ADNI Harmonized Protocol working group [Giovanni B. Frisoni, Abstract #42]

Structural and molecular imaging of neurodegeneration: a new hybrid PET-MR protocol [Valentina Garibotto, Abstract #46]

The relationship between Alzheimer’s pathology and white matter degeneration; Preliminary CSF study [Hee-Jin Kim, Abstract #78]

The longitudinal cognitive impact of the white matter hyperintensities to the patients with mild to moderate Alzheimer’s disease [Bon Ku, Abstract #82]

Assessment of Alzheimer’s disease (AD) progression in AD transgenic mice by PET imaging with [F-18] hydroxy quinoline [Padmakar Kulkarni, Abstract #83]

Determining rate of decline in amyloid positive pre-AD AIBL participants using regular brief cognitive assessments [Paul Maruff, Abstract #97]
Influence of ApoE genotype on amyloid PET-ligand binding and correlation to pathology in human post mortem brain tissue [Anna Mattsson, Abstract #99]

Frontotemporal dementia multimodal MRI study [Miguel Ángel Muñoz Ruiz, Abstract #106]

Characterization of PET amyloid tracers in autopsy Alzheimer brain [Ruiqing Ni, Abstract #108]

Cortical thinning in ADNI patients: how good is automated reconstruction? [Alberto Redolfi, Abstract #116]

Default mode network connectivity in Alzheimer’s disease and Parkinson’s disease dementia [Irena Rektorova, Abstract #117]

In vitro imaging of GSK3 for target expression and drug target engagement studies [Johan Sandell, Abstract #129]

Low PIB PET retention in the presence of pathological other AD biomarkers in Arctic APP mutation carriers [Michael Schöll, Abstract #135]

A MR based atrophy index measuring the severity of Alzheimer’s disease-like pathology in predementia cases [Gabriela Spulber, Abstract #142]

Brain perfusion changes in patients with Alzheimer’s disease and dementia with Lewy bodies [Maja Trošt, Abstract #155]

Combining MRI and CSF measures for classification of Alzheimer’s disease and prediction of mild cognitive impairment conversion [Eric Westman, Abstract #165]

The effects of white matter hyperintensities on cognitive impairment in patients with amnestic mild cognitive impairment [Bora Yoon, Abstract #171]

Prefrontal cortex rTMS enhances action naming in progressive non-fluent aphasia [Orazio Zanetti, Abstract #172]

Chronic inhibition of the MEK/ERK pathway fails to delay disease progression in a transgenic animal model of tauopathy [Annalisa Cavallini, Abstract #19]

Coenzyme Q10 restores Amyloid beta-inhibited proliferation of neural stem cells by activating the PI3K Pathway [Hojin Choi, Abstract #21]

Difference of amyloid burden increase by APOE genotype in cognitively normal elderly: PIB-PET Study [Il Han Choo, Abstract #23]
Preclinical evaluation of a novel small molecule BACE1 inhibitor in vivo
[Susanna Eketjäll, Abstract #33]

NPT101 produces rapid and persistent Abeta lowering in aged TG2576 mice
[Richard Fisher, Abstract #38]

Identification of novel synaptic γ-secretase associated proteins and their effect on APP and Notch processing [Susanne Frykman, Abstracts #43]

An amyloid-β binding peptide modulates Aβ oligomerization and is a possible candidate for therapy of Alzheimer's disease [Susanne Aileen Funke, Abstract #44]

Inhibition of GSK3β improves synaptic function and cognition in mice
[Biljana Georgievksa, Abstract #47]

Acute effect of a glycogen synthase kinase-3 inhibitor on phosphorylated and total tau in P301L transgenic mice [Olof Gissberg, Abstract #49]

The role of alpha 7 agonism for regulation of brain Abeta levels in aged TG2576 APPSWE mice [Tom J. Goldschmidt, Abstract #50]

β-amyloid impairs the nicotinic-stimulated neurotransmitter release in rat hippocampus in absence of neurotoxicity [Stefano Govoni, Abstract #52]

Shifting the balance from neurodegeneration to regeneration: A novel therapeutic approach to Alzheimer’s disease [Inge Grundke-Iqbal, Abstract #54]

A longitudinal characterization of synaptic markers in the tg2576 amyloid mouse model [Kina Höglund, Abstract #63]

The proximity ligation assay shows interaction between novel γ-secretase associated proteins and γ-secretase [Mitsuhiro Inoue, Abstract #66]

In vitro properties of a novel BACE1 inhibitor for the treatment of Alzheimer’s disease [Fredrik Jeppsson, Abstract #72]

MGlUR5 in the Abeta oligomer hypothesis [Pascale N. Lacor, Abstract #85]

A review and analysis of γ-secretase inhibitor trials; has Aβ production inhibition been adequately validated as therapeutic approach in mild AD? [Johan Lundkvist, Abstract #92]

Effect of Aβ burden and apolipoprotein E genotype on cognitive decline at 18 months in healthy older adults [Paul Maruff, Abstract #98]

Subcellular targeting of Aβ oligomers with conformational intrabodies [Giovanni Meli, Abstract #101]
H GAMMA SECRETASE – BETA SECRETASE – Aβ – TAU – APP – APOE (continued)

Characterization of the young rat model with regards to effects on hippocampal Tau phosphorylation [Anette Mörtberg, Abstract #105]

Early aggregates in the self-assembly process of the amyloid β peptide [Luitgard Nagel-Steger, Abstract #107]

The role of Aph-1 homologues for APP and Notch processing [Annelie Pamrén, Abstract #109]

ApoE4 compromises Thioredoxin 1 (TRX1) levels in brain, activating the apoptosis signaling cascade [Torbjörn Persson, Abstract #114]

Mitochondrial function in a transgenic mouse model expressing human APP with the Arctic mutation [Annica Rönnbäck, Abstract #125]

Modulation of gamma-secretase by Apolipoprotein E [Marta Rubio-Rodrigo, Abstract #126]

γ-Secretase inhibitor treatment results in impaired behavior in the contextual fear conditioning test in the mouse [Johan Sandin, Abstract #130]

Studies of the interaction between gamma-secretase and NDUFS7 with in situ proximity ligation assay [Sophia Schedin Weiss, Abstract #134]

Aβ16-23’ peptide – a potential inhibitor of RAGE-dependent Aβ40 endocytosis in bEnd.3 cells [Joanna Stepek, Abstract #145]

GSAP - a therapeutic target for Alzheimer’s disease? [Kia Strömberg, Abstract #146]

Safety profile of 1054 placebo treated Alzheimer’s disease patients during the IDENTITY studies [Karen L. Sundell, Abstract #148]

MARK2 and Tau frequently interact in pSer262-immunopositive neurons of Alzheimer’s disease brain revealed by proximity ligation [Dan Sunnemark, Abstract #149]

A novel, potent, and selective modulator of gamma secretase [Barbara Tate, Abstract #150]

Pharmacological evaluation of novel highly active AD-relevant protein kinase inhibitors [Volkmar Tell, Abstract #151]

Behavioural effects of selenium in mouse models of Alzheimer’s disease [Ann Van der Jeugd, Abstract #157]

Expression of MARK1, 2, 3, and 4 in AD brain [Gabriel von Euler, Abstract #159]

Impact of different γ-secretase modulators on Notch-1 Abeta-like peptide (Nβ) formation [Johanna Wanngren, Abstract #163]
<table>
<thead>
<tr>
<th>Category</th>
<th>Category Description &amp; Poster Titles [Note: Presenting author only is listed]</th>
</tr>
</thead>
<tbody>
<tr>
<td>H</td>
<td>GAMMA SECRETASE – BETA SECRETASE – Aβ – TAU – APP – APOE (continued)</td>
</tr>
</tbody>
</table>

The Aβ-oligomer targeting D-peptide D3 is efficiently improving pathology and cognition of orally treated transgenic AD mice [Dieter Willbold, Abstract #169]

I | NEUROPSYCHOLOGY – BEHAVIOR – COGNITION                              |
|---------------------------------|---------------------------------------------------------------------|

Abstracts 1, 3, 7, 24, 25, 56, 57, 75, 76, 77, 79, 86, 93, 102, 103, 111, 137, 140, 153, 154

Surprising similarities: neuropsychological impairments assessed by means of a computer-based test in Alzheimer and Multiple Sclerosis patients [Georg Adler, Abstract #1]

Computer-based assessment of memory and attention in patients with Alzheimer’s dementia [Georg Adler, Abstract #3]

Episodic memory is associated with PET measures of beta-amyloid, inflammation and glucose metabolism in preclinical and clinical AD [Ove Almkvist, Abstract #7]

Use of the doll with dementia-affected patients with behavior disturbances in a nursing home for Alzheimer patients [Ivo Cilesi, Abstract #24]

Therapeutic virtual train with dementia-affected patients with behaviour disturbances in a nursing home for Alzheimer patients [Ivo Cilesi, Abstract #25]

Feelings of hopelessness in midlife are associated with dementia risk in later life [Krister Håkansson, Abstract #56]

Effects of melatonin on sleep deprivation-induced cognitive impairment [Seol-Heui Han, Abstract, #57]

Validation of ADAS-COG and NTB used in a clinical study with Alzheimer’s disease patients [Aleksandra Karin, Abstract #75]

Validation of COGSTATE cognitive test battery used in a clinical study with Alzheimer’s disease patients [Aleksandra Karin, Abstract #76]

Characteristics of Behavioral Psychiatric Symptoms of Amyotrophic Lateral Sclerosis with Frontotemporal lobar Degeneration according to the subtypes [Hee-Jin Kim, Abstract #77]

CERAD-NB total score - a valid method for the follow-up of cognition in patients with Alzheimer’s disease: Kuopio ALSOVA study [Anne M. Koivisto, Abstract #79]

Synaptic and cytoskeletal changes in Alzheimer’s disease and depression [Andrew C.K. Law, Abstract #86]

Neuropsychological assessment in diagnosis of Dementia [Dulce Maia, Abstract #93]

Use of physical restraints in hospitalized elderly: experience with severely demented patients [Aline Mendes, Abstract #102]
Attention-related potentials allow for a highly accurate discrimination of MCI subtypes [Pascal Missonnier, Abstract #103]

Sleep problems are associated with behavioral symptoms as well as cognitive functions in dementia patients [Kee Hyung Park, Abstract #111]

Neuropsychological Differences between Apolipoprotein E4 positive and negative subgroups in Alzheimer’s Disease [Joon Hyun Shin, Abstract #137]

Relationship between cognitive screening results and measure of episodic memory in early Alzheimer’s disease [Maja Smrdu, Abstract #140]

Cognitive and performance-based functional measures predicting mortality in elderly medical inpatients [Gustav Torisson, Abstract #153]

InOut Test: Diagnosis of potential converters from Mild Cognitive Impairment (MCI) and Subjective Memory Complaints (SMC) to dementia by a new cognitive paradigm [Eduardo Torrealba, Abstract #154]
Save the Date

Mechanisms, clinical strategies, and promising treatments of neurodegenerative diseases

The 11th International Conference On Alzheimer’s & Parkinson’s Diseases

AD/PD™ 2013

Florence, Italy, March 6-10, 2013
www.kenes.com/adpd

Important Dates
Deadline for the Submission of Abstracts
Wednesday, October 10, 2012
Early Registration Deadline
Tuesday, December 11, 2012

Visit AD/PD™ 2013 via your smartphone by scanning this image
This is a QR Code (Quick Response Code). Scanning this code with an app such as QR Reader [free] on your smartphone or other smart device will access a pdf file where you can read the text of the poster abstracts from the 12th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. The link embedded in the QR Code will open to the poster index page with hyperlinks to each individual abstract. [www.ad-springfield.com/2012abstracts.pdf]